Technologies
A platform built for complex modalities
Antibody-drug conjugates and engineered formats place demands that standard biologics manufacturing was never designed for: precise conjugation chemistry, contained handling of potent payloads, and analytics that can resolve heterogeneity others cannot see. Our platform brings conjugation, antibody engineering, microbial and mRNA/LNP capability together under one contained roof — so the science and the manufacturing develop in step.
Our approach
Chemistry and format, engineered together
A conjugate is only as good as the antibody, the linker and the payload acting as one. We design the format and the conjugation chemistry in parallel — selecting site-specific or stochastic approaches, matching linker stability to the payload, and controlling drug-to-antibody ratio toward a homogeneous, well-characterised product.
Candidate chemistries and formats are screened on small scale, ranked against developability, potency and analytical criteria, and confirmed with DAR, free-drug and aggregation data before a programme commits to a single route to GMP.
Platform capabilities
The specialized-modality toolbox
A complementary set of conjugation, antibody-engineering, microbial, mRNA/LNP, containment and analytical capabilities — applied individually or as an integrated programme.
Bioconjugation & ADC development
Site-specific and stochastic conjugation chemistries, linker-payload selection, and drug-to-antibody ratio (DAR) control to deliver homogeneous, well-characterised conjugates.
Engineered antibody formats
Bispecifics and multispecifics, antibody fragments (Fab, scFv, VHH) and Fc-engineering — designed for manufacturability as well as biology.
Microbial fragment manufacturing
E. coli and microbial production of antibody fragments, scaffolds and conjugation-ready intermediates — an efficient route for non-glycosylated formats.
mRNA & lipid nanoparticles
mRNA drug-substance production and lipid-nanoparticle (LNP) formulation, supporting emerging modalities alongside our antibody and conjugate work.
High-potency, contained manufacturing
Handling of cytotoxic payloads and potent intermediates to high containment (OEB) standards, protecting operators and product throughout conjugation and processing.
Analytics for complex modalities
DAR, free-drug, aggregation, identity and potency assays purpose-built for conjugates and engineered formats — resolving heterogeneity that standard biologics methods miss.
Principles
How we engineer for manufacturability
Design the chemistry and the format together
Conjugation site, linker and payload are chosen alongside the antibody format and its analytics — so the molecule is characterisable and controllable, not just active.
Containment is built in, not bolted on
Potent-payload handling, OEB controls and operator protection are designed into the process from the first conjugation step through to GMP drug substance.
Analytics define the product
DAR distribution, free drug, aggregation and potency are the control levers for a conjugate. We develop those assays early so the product is defined by data, not assumption.
Where this matters
Programmes we're built for
Conjugates & high-potency biologics
ADCs and bioconjugates carrying cytotoxic payloads, where contained handling, controlled DAR and conjugate-specific analytics decide whether the molecule can be manufactured and supplied to GMP.
Next-generation & non-standard formats
Bispecifics, fragments, Fc-engineered antibodies and adjacent modalities whose biology has outrun standard platforms — and which need purpose-built process and analytical development.
See how the platform maps to your stage
From a first feasibility study to GMP drug substance and product, our services flex to where your programme is today.